ALLGNHL32 Study - An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma (2021–2024)
- Grant type:
- Australasian Leukaemia & Lymphoma Group
- Researchers:
-
-
- Funded by:
- Australasian Leukaemia & Lymphoma Group
